The US Food and Drug Administration (FDA) has聽for Eisai and Biogen鈥檚 Leqembi (lecanemab-irmb) 100mg/mL injection to treat Alzheimer鈥檚 disease (AD) in adults.
With the approval of the supplemental biologics licence application (sBLA), Leqembi becomes the first therapy to slow disease progression rate and cognitive and functional decline in AD patients.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This development is based on findings from the Phase III portion of Eisai鈥檚 Clarity AD clinical trial.
Trial data showed that the product met the Leqembi primary endpoint and all crucial secondary endpoints, and also demonstrated clinical benefit.
In January 2023, the regulatory agency granted accelerated approval for Leqembi.
Leqembi is a humanised immunoglobulin gamma 1 (IgG1) monoclonal antibody that targets aggregated soluble (protofibril) and amyloid beta鈥檚 (A尾) insoluble forms.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataEisai CEO Haruo Naito stated: 鈥淭he FDA approved Leqembi under the traditional approval pathway, making Leqembi the first and only approved anti-amyloid Alzheimer鈥檚 disease treatment shown to reduce the rate of disease progression and to slow cognitive impairment in the early and mild dementia stages of the disease.
鈥淎s a research and development-focused company based on our human health care concept, we are proud that the results of Eisai鈥檚 AD research over the past 40 years have been recognised and delivered to people living with this disease in the United States.鈥�
